Clinical Trials

Are you an adult who has asthma, or are you willing to be a healthy volunteer? This study is looking at the DNA in airway cells to see how they differ between people who have asthma and people who do not. To get a sample of cells from your airways, you may have a bronchoscopy (a tube inserted through your mouth into your airways). To participate in this study, you must be between 18 and 70 years old, either with asthma or with no history of asthma. This study is located in San Francisco, California.

Do you have asthma and obesity and live near Aurora, Colorado? Obesity can lead to widespread inflammation that may make asthma worse. This study will test whether a medicine called CXA-10 reduces inflammation in the airways and body and improves asthma symptoms in people who have obesity. To participate in this study, you must be between 18 and 65 years old, have a BMI of 30 or greater, and have been on long-acting controller medicine—such as inhaled corticosteroids or long-acting beta2-agonists—for at least three months. This study is located in Aurora, Colorado.

Are you an adult with both asthma and obesity? This study is testing whether a medicine called L-citrulline can help treat asthma and improve lung function in people who have obesity. To participate in this study, you must be 18 to 65 years old and have asthma and obesity. This study takes place in Durham, North Carolina.

Has your child been treated for an asthma attack with an oral corticosteroid medicine in the last 12 months? A study team will recruit 60 teens and young adults (between 12 and 21 years old) with persistent asthma who are at high risk for future exacerbation. This study examines the contribution of interleukin 1 beta (IL-1β), a protein that is involved in the inflammatory response, in asthma flare-ups. This study takes place in Chapel Hill, North Carolina.

The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the peripheral vasculature. Because of the unique design of the catheter, with its six expandable infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple arms of the basket in the infusion catheter causes fissuring of the clot. The net result is that a greater surface area of clot is exposed to both endogenous and exogenously administered lytic agents, thereby promoting clot dissolution.

Do you or your child have a platelet, bleeding, or white blood cell disorder? This study is looking at people who have platelet or other blood disorders. The researchers will use a blood sample to look for problems with platelets and a possible genetic cause in the participant’s DNA or RNA. To participate in this study, you must be a child or adult who either is healthy or has a platelet disorder, coagulation disorder, or white blood cell disorder. This study is located in New York, New York.

The purpose of this study is to determine the occurrence of scarring of the heart (cardiac fibrosis) and inflammation in those with perinatally acquired Human Immunodeficiency Virus (HIV) infection compared to people not infected with HIV. The information learned from this research may help the investigator to better understand the link between cardiac fibrosis and cardiac dysfunction and inflammation in those with perinatally acquired HIV infection compared to the uninfected.

The purpose of this study is to non-invasively characterize the fibrotic consequences of single ventricle physiology, its possible solution and effect on lymphatics. This project investigates the response to acute imposition of Fontan hemodynamics by examining the interrelationship between liver and cardiac fibrosis/dysfunction and lymphatic congestion along with a pilot trial of the antifibrotic agent, spironolactone, to prevent these consequences and to determine if MRI can discern these differences. The combination of serum biomarkers and MRI form a powerful non-invasive tool in putting together this complicated web of dysfunction.

The purpose of this study is to see if adding a drug called Regadenoson to the EVLP circulation reservoir during perfusion of marginal donor lungs will help increase the likelihood that the donor lungs will become usable for transplantation.

The purpose of this study is to determine if acquired (partial) Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) deficiency contributes substantially to the pathogenic mechanisms underlying Chronic Rhinosinusitis (CRS), creating a localized environment that impairs mucociliary clearance (MCC).